Loading...
•
Mar 31, 2023
Keros Q1 2023 Earnings Report
Keros reported financial results for the quarter ended March 31, 2023.
Key Takeaways
Keros Therapeutics reported a net loss of $35.8 million in the first quarter of 2023, compared to a net loss of $24.2 million in the first quarter of 2022. The company's cash and cash equivalents totaled $351.4 million as of March 31, 2023.
Keros is on track to report additional data from multiple clinical trials this year.
Cash position strengthened through the sale of additional shares of common stock.
Keros appointed Dr. Alpna Seth, Ph.D., to its board of directors in May 2023.
Keros will present three poster abstracts from its KER-012 program at the American Thoracic Society (“ATS”) 2023 International Conference.
Forward Guidance
Keros expects that the cash and cash equivalents it had on hand at March 31, 2023 will enable Keros to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...